Literature DB >> 28490638

Immunomodulation via Toll-like Receptor 9: An Adjunct Therapy Strategy against Alzheimer's Disease?

Maria Clara Selles1, Juliana Tiemi Sato Fortuna1, Luís Eduardo Santos2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28490638      PMCID： PMC6596480          DOI： 10.1523/JNEUROSCI.0579-17.2017

Source DB:  PubMed          Journal:  J Neurosci        ISSN： 0270-6474            Impact factor:   6.167


× No keyword cloud information.
  21 in total

Review 1.  CpG motifs in bacterial DNA and their immune effects.

Authors:  Arthur M Krieg
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

Review 2.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

3.  Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology.

Authors:  Henrieta Scholtzova; Richard J Kascsak; Kristyn A Bates; Allal Boutajangout; Daniel J Kerr; Harry C Meeker; Pankaj D Mehta; Daryl S Spinner; Thomas Wisniewski
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

4.  CpG-containing oligodeoxynucleotide promotes microglial cell uptake of amyloid beta 1-42 peptide by up-regulating the expression of the G-protein- coupled receptor mFPR2.

Authors:  Pablo Iribarren; Keqiang Chen; Jinyue Hu; Wanghua Gong; Edward H Cho; Stephen Lockett; Badarch Uranchimeg; Ji Ming Wang
Journal:  FASEB J       Date:  2005-10-11       Impact factor: 5.191

5.  Toll-like receptor 9 can be expressed at the cell surface of distinct populations of tonsils and human peripheral blood mononuclear cells.

Authors:  Ashlyn Eaton-Bassiri; Susan B Dillon; Mark Cunningham; Michael A Rycyzyn; Juliane Mills; Robert T Sarisky; M Lamine Mbow
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

6.  Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease.

Authors:  Yukiko Doi; Tetsuya Mizuno; Yuki Maki; Shijie Jin; Hiroyuki Mizoguchi; Masayoshi Ikeyama; Minoru Doi; Makoto Michikawa; Hideyuki Takeuchi; Akio Suzumura
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

7.  Up-regulation of FPR2, a chemotactic receptor for amyloid beta 1-42 (A beta 42), in murine microglial cells by TNF alpha.

Authors:  Y H Cui; Y Le; X Zhang; W Gong; K Abe; R Sun; J Van Damme; P Proost; J M Wang
Journal:  Neurobiol Dis       Date:  2002-08       Impact factor: 5.996

8.  Toll-like receptor 9: a new target of ischemic preconditioning in the brain.

Authors:  Susan L Stevens; Thomas M P Ciesielski; Brenda J Marsh; Tao Yang; Delfina S Homen; Jo-Lynn Boule; Nikola S Lessov; Roger P Simon; Mary P Stenzel-Poore
Journal:  J Cereb Blood Flow Metab       Date:  2008-01-09       Impact factor: 6.200

9.  How location governs toll-like receptor signaling.

Authors:  Akanksha Chaturvedi; Susan K Pierce
Journal:  Traffic       Date:  2009-06       Impact factor: 6.215

10.  Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

Authors:  S Gilman; M Koller; R S Black; L Jenkins; S G Griffith; N C Fox; L Eisner; L Kirby; M Boada Rovira; F Forette; J-M Orgogozo
Journal:  Neurology       Date:  2005-05-10       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.